Abstract:Background Adoptive cancer immunotherapy, using engineered T-cells, expressing chimeric antigen receptor or autologous tumor infiltrating lymphocytes became, in recent years, a major therapeutic approach for diverse types of cancer. However, despite the transformative potential of adoptive cancer immunotherapy, this field still faces major challenges, manifested by the apparent decline of the cytotoxic capacity of effector CD8 + T cells upon their expansion. To address these challenges, we have developed an ex vivo “synthetic immune niche” (SIN), composed of immobilized CCL21 and ICAM1, which synergistically induce an efficient expansion of antigen-specific CD8 + T cells while retaining, and even enhancing their cytotoxic potency. Methods To explore the molecular mechanisms through which a CCL21+ICAM1-based SIN modulates the interplay between the proliferation and cytotoxic potency of antigen-activated and CD3/CD28-activated effector CD8 + T cells, we performed integrated analysis of specific differentiation markers via flow cytometry, together with gene expression profiling. Results On day 3, the transcriptomic effect induced by the SIN was largely similar for both dendritic cell (DC)/ovalbumin (OVA)-activated and anti-CD3/CD28-activated cells. Cell proliferation increased and the cells exhibited high killing capacity. On day 4 and on, the proliferation/cytotoxicity phenotypes became radically “activation-specific”; The DC/OVA-activated cells lost their cytotoxic activity, which, in turn, was rescued by the SIN treatment. On longer incubation, the cytotoxic activity further declined, and on day7, could not be rescued by the SIN. SIN stimulation following activation with anti-CD3/CD28 beads induced a major increase in the proliferative phenotype while transiently suppressing their cytotoxicity for 2–3 days and fully regaining their killing activity on day 7. Potential molecular regulatory pathways of the SIN effects were identified, based on transcriptomic and multispectral imaging profiling. Conclusions These data indicate that cell proliferation and cytotoxicity are negatively correlated, and the interplay between them is differentially regulated by the mode of initial activation. The SIN stimulation greatly enhances the cell expansion, following both activation modes, while displaying high survival and cytotoxic potency at specific time points following stimulation, suggesting that it could effectively reinforce adoptive cancer immunotherapy.

Cancer cell-intrinsic biosynthesis of itaconate promotes tumor immunogenicity

Itaconate is a Lysosomal Inducer That Promotes Antibacterial Innate Immunity.

Itaconate Regulates Macrophage Function Through Stressful Iron-Sulfur Cluster Disrupting And Iron Metabolism Rebalancing

Itaconate Uptake Via SLC13A3 Improves Hepatic Antibacterial Innate Immunity

The Cell Autonomous and Non-Autonomous Roles of Itaconate in Immune Response

The Emerging Application of Itaconate: Promising Molecular Targets and Therapeutic Opportunities.

Itaconate promotes hepatocellular carcinoma progression by epigenetic induction of CD8+ T-cell exhaustion

Targeting IRG1 reverses the immunosuppressive function of tumor-associated macrophages and enhances cancer immunotherapy

Metabolite itaconate in host immunoregulation and defense

Synthetic Enforcement of STING Signaling in Cancer Cells Appropriates the Immune Microenvironment for Checkpoint Inhibitor Therapy.

Tumor-associated macrophage-derived itaconic acid contributes to nasopharyngeal carcinoma progression by promoting immune escape via TET2

Itaconate: A Metabolite Regulates Inflammation Response and Oxidative Stress

A Tumor Acidity Activatable and Ca2+-assisted Immuno-Nanoagent Enhances Breast Cancer Therapy and Suppresses Cancer Recurrence

The signaling pathways and therapeutic potential of itaconate to alleviate inflammation and oxidative stress in inflammatory diseases

Control of immune cell signaling by the immuno-metabolite itaconate

ATPIF1 Inactivation Promotes Antitumor Immunity Through Metabolic Reprogramming of CD8+ T Cells

Enhancement of tumor immunogenicity by the introduction of non- proteinogenic amino acid azetidine-2-carboxylic acid

Intrinsic RIG-I restrains STAT5 activation to modulate antitumor activity of CD8+ T cells

Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1

Tumorous expression of NAC1 restrains antitumor immunity through the LDHA-mediated immune evasion

Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy